NCT07099157View on ClinicalTrials.gov

Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Herpes Zoster
Interventions
DRUG

Brivudine

brivudine 125 mg per dose, once daily, 7 days

DRUG

Famciclovir

orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days

Trial Locations (4)

Unknown

Air Force Medical Center, PLA, Beijing

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing

Peking University First Hospital, Beijing

Xuanwu Hospital, Capital Medical University, Beijing

All Listed Sponsors
collaborator

Peking University First Hospital

OTHER

collaborator

Air Force Military Medical University, China

OTHER

collaborator

Beijing Hospital of Traditional Chinese Medicine

OTHER

collaborator

Xuanwu Hospital, Beijing

OTHER

lead

Peking University Third Hospital

OTHER